Patent ID: 6610323
Filing Date: 2003-08-26
Classification: A61K,A61P

Abstract:
An enteric coated pharmaceutical dosage form comprising an H+,K+-ATPase inhibitor, a distruptable semi-permeable membrane and one or more swellable substances, wherein the dosage form has an instant inhibitor-releasing part and at least one delayed inhibitor-releasing part, and is capable of giving a discontinuous release of the H+,K+-ATPase inhibitor in the form of at least two consecutive pulses separated in time from 0.5 up to 12 hours, and the H+,K+-ATPase inhibitor is a compound of the formula I whereinHet1 is Het2 is X=whereinN in the benzimidazole moiety means that one of the ring carbon atoms substituted by R6-R9 optionally may be exchanged for a nitrogen atom without any substituents; R1, R2 and R3 are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, fluorine-substituted alkoxy, alkylthio, alkoxyalkoxy, dialkylamino, piperidino, morpholino, halogen, phenyl and phenylalkoxy; R4 and R5 are the same or different and selected from the group consisting of hydrogen, alkyl and arylalkyl; R6â€² is selected from the group consisting of hydrogen, halogen, trifluoromethyl, alkyl and alkoxy, R6-R9 are the same or different and selected from the group consisting of hydrogen, alkyl, alkoxy, halogen, haloalkoxy, alkylcarbonyl, alkoxycarbonyl, oxazolinyl, and trifluoroalkyl, or adjacent groups R6-R9 form ring structures; R10 is hydrogen or forms an alkylene chain together with R3; and R11 and R12 are the same or different and selected from the group consisting of hydrogen, halogen and alkyl.